Elevated N-cadherin levels in ovarian cancer are associated with poorer outcomes, particularly in the mesenchymal molecular subtype, which correlates with severe complications and poor prognosis (Loret et al., 2019). This evidence concerns the gene CDH2 and ovarian cancer.